10 February 2022 : Clinical Research
A Single-Center, Randomized, Double-Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis with and without Rivaroxaban
Zi-Yan Wang1ABC, You-Dong Wan2CDEF, Xian-Zhi Liu1EFG, Hao Wang1AD, Guang-Yi Jiang1ABF, Bo Yang1ABCDEFG*DOI: 10.12659/MSM.934341
Med Sci Monit 2022; 28:e934341
Table 1 Baseline characteristics of participants with rivaroxaban and placebo.
| Parameter | Rivaroxaban (n=47) | Placebo (n=47) | P value |
|---|---|---|---|
| Age (year) (mean±SD) | 53.87±7.66 | 54.10±6.46 | 0.87 |
| Sex (Female( | 29 (61.7%) | 26 (55.3%) | 0.53 |
| BMI (mean±SD) | 22.04±2.48 | 22.04±3.02 | 0.62 |
| Laboratory tests | 0.31 | ||
| Platelets (×10/L) | 177.57±43.02 | 171.06±37.59 | 0.43 |
| Hemoglobin (g/L) | 150.09±12.77 | 149.38±9.02 | 0.76 |
| Medical history | 8 (17.0%) | 7 (14.9%) | 0.77 |
| Diabetes | 3 (6.4%) | 2 (4.3%) | |
| Coronary artery disease | 1 (2.1%) | 2 (4.3%) | |
| Venous thromboembolism | 1 (2.1%) | 0 | |
| Stroke | 1 (2.1%) | 4 (8.5%) | |
| Hypertension | 5 (10.6%) | 2 (4.3%) | |
| WHO Glioma grade | |||
| I, II | 11 (23.4%) | 14 (29.8%) | 0.48 |
| III, IV | 36 (76.6%) | 33 (70.2%) | 0.48 |
| Histological type | |||
| Oligodendroglioma | 2 (4.3%) | 4 (8.5%) | |
| Astrocytoma | 5 (10.6%) | 6 (12.8%) | |
| Mixed glioma | 4 (8.5%) | 4 (8.5%) | |
| Anaplastic glioma | 10 (21.3%) | 11 (23.4%) | |
| Glioblastoma | 23 (48.9%) | 18 (38.3%) | |
| Other malignant glioma | 3 (6.4%) | 4 (8.5%) | |
| SD – standard deviation; BMI – body mass index. | |||